A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.
Citations
52 citations
Cites background or methods from "A Next Generation Connectivity Map:..."
...…et al, 2007; Médard et al, 2015) and cellular thermal shift assay (Savitski et al, 2014) to measure drug– protein interactions, and multiplexed imaging or flow-cytometry to measure multiple cellular parameters upon drug treatment (Li et al, 2017; Subramanian et al, 2017; Reinecke et al, 2019)....
[...]
...…license Molecular Systems Biology 16: e9405 | 2020 1 of 14 Pharmacological screens (Barretina et al, 2012; Garnett et al, 2012; Iorio et al, 2016; Subramanian et al, 2017; Lee et al, 2018) have been used to profile the activity of hundreds of compounds in highly annotated collections of cancer…...
[...]
...Parallel integration of gene loss-of-function screens with drug response can be used to investigate drug mechanism-of-action (Deans et al, 2016; Subramanian et al, 2017; Jost & Weissman, 2018; Wang et al, 2018; Zimmermann et al, 2018; Hustedt et al, 2019a,b)....
[...]
52 citations
51 citations
50 citations
50 citations
Cites methods from "A Next Generation Connectivity Map:..."
...…data sets can be expected to be generated as part of future efforts that utilize high-throughput transcriptomics technologies similar to the TempO-seq Tox21 Phase III L1500þ or the Broad Institute Connectivity Map L1000 platform (Andersen et al. 2015; Collins et al. 2017; Subramanian et al. 2017)....
[...]
References
34,830 citations
30,124 citations
10,968 citations
8,326 citations
6,319 citations